Patents by Inventor Gary R. Pasternack
Gary R. Pasternack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230404956Abstract: This invention is directed to citrulline therapy, where citrulline is administered to achieve a newly recognized therapeutic window. The results of a completed clinical trial has elucidated a therapeutic window for L-citrulline. Detailed analysis of clinical outcome as a function of the dose actually received reveals that patients falling within the dosing window showed significant improved effect compared to patients receiving a dose either below or above the dosing window. Patients benefiting from this invention are patients in need of supplemental citrulline to ensure that adequate nitric oxide levels are produced by endothelial tissues.Type: ApplicationFiled: June 21, 2022Publication date: December 21, 2023Inventors: Gurdyal Kalsi, Marshall Summar, Frederick E. Barr, Omar Ayyub, Gary R. Pasternack
-
Publication number: 20130164374Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: February 21, 2013Publication date: June 27, 2013Applicant: Intralytix, Inc.Inventors: J. Glenn MORRIS, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Publication number: 20120148505Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: August 22, 2011Publication date: June 14, 2012Applicant: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 8003323Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: GrantFiled: November 4, 2008Date of Patent: August 23, 2011Assignee: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 7745194Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.Type: GrantFiled: September 16, 2008Date of Patent: June 29, 2010Assignee: Intralytix, Inc.Inventors: Gary R. Pasternack, Alexander Sulakvelidze
-
Patent number: 7674467Abstract: The present invention is directed to isolated Salmonella bacteriophage, and methods of using Salmonella bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Salmonella. The present invention also contemplates the use of Salmonella bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Salmonella.Type: GrantFiled: September 3, 2004Date of Patent: March 9, 2010Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Shanmuga Sozhamamnnan, Gary R. Pasternack
-
Patent number: 7635584Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.Type: GrantFiled: May 31, 2007Date of Patent: December 22, 2009Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Gary R. Pasternack
-
Publication number: 20090297561Abstract: The invention provides methods of generating phage lysate bacterins, as well as phage lysate bacterin compositions. The invention further encompasses methods of vaccination comprising administering phage lysate bacterin to an animal in need thereof. The invention further encompasses methods of reducing infection or colonization of poultry or poultry eggs using phage bacterin lysates. Method of vaccination comprising administering to an animal in need of immunization an amount of phage lysate bacterin to induce an immune response.Type: ApplicationFiled: September 3, 2004Publication date: December 3, 2009Applicant: IntralytixInventors: Gary R. Pasternack, Alexander Sulakvelidze, Torrey Brown
-
Patent number: 7625556Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli in various settings.Type: GrantFiled: December 12, 2007Date of Patent: December 1, 2009Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Gary R. Pasternack
-
Patent number: 7625741Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.Type: GrantFiled: December 12, 2007Date of Patent: December 1, 2009Assignee: Intralytix, Inc.Inventors: Gary R. Pasternack, Alexander Sulakvelidze
-
Patent number: 7625739Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Clostridium perfringens, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Clostridium perfringens in various settings.Type: GrantFiled: August 14, 2007Date of Patent: December 1, 2009Assignee: Intralytix, Inc.Inventors: Gary R. Pasternack, Alexander Sulakvelidze
-
Patent number: 7625740Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Clostridium perfringens, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Clostridium perfringens in various settings.Type: GrantFiled: August 17, 2007Date of Patent: December 1, 2009Assignee: Intralytix, Inc.Inventors: Gary R. Pasternack, Alexander Sulakvelidze
-
Patent number: 7622293Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Pseudomonas aeruginosa, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Pseudomonas aeruginosa in various settings.Type: GrantFiled: June 18, 2007Date of Patent: November 24, 2009Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Gary R. Pasternack
-
Patent number: 7507571Abstract: The present invention is directed to isolated Listeria monocytogenes bacteriophage, and methods of using Listeria monocytogenes bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Listeria monocytogenes. The present invention also contemplates the use of Listeria monocytogenes bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Listeria monocytogenes.Type: GrantFiled: June 18, 2007Date of Patent: March 24, 2009Assignee: Intralytix, Inc.Inventors: Gary R. Pasternack, Alexander Sulakvelidze
-
Publication number: 20090053144Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: November 4, 2008Publication date: February 26, 2009Applicant: Intralytix, IncInventors: J. Glenn MORRIS, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 7459272Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: GrantFiled: December 2, 2003Date of Patent: December 2, 2008Assignee: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
-
Patent number: 7385086Abstract: This invention provides compounds and methods for treating, with said compound, a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SOn-Z-CO—Y, where R is an alkyl groups having 6-20 carbon atoms, unsaturated hydrocarbon groups having 6-20 carbon atoms, or alkyl groups having 6-20 carbon atoms interrupted by at least one aromatic ring; Z is —CH2—, —CH2CH2—, —NH—NH—, —O—, ——NH—, —O—NH—, —CH2—NH—, —CH2—O—, —NH—O—, —NH—CH2—, —O—CH2—, and —CH?CH—; Y is —NH2, —O—CH2—C6H5, —CO—CO—O—CH3, and —O—CH3; and n is 1 or 2. It has been discovered that these compounds treat microbially-based infections caused by corynebacteria, nocardiae, rhodococcus, and mycobacteria. These compounds may be used to treat mycobacterial cells, such as Mycobacteria tuberculosis, drug resistant M. tuberculosis, M. avium intracellulare, M. leprae, M. paratuberculosis, and pathogenic Mycobacteria sp.Type: GrantFiled: January 27, 2004Date of Patent: June 10, 2008Assignee: The Johns Hopkins University School of MedicineInventors: Craig A. Townsend, James D. Dick, Gary R. Pasternack, Francis P. Kuhajda, Nicole M. Parrish
-
Publication number: 20080118468Abstract: The present invention is directed to isolated Salmonella bacteriophage, and methods of using Salmonella bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Salmonella. The present invention also contemplates the use of Salmonella bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Salmonella.Type: ApplicationFiled: September 3, 2004Publication date: May 22, 2008Applicant: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Shanmuga Sozhamamnnan, Gary R. Pasternack
-
Patent number: 6930175Abstract: pp32 is a member of a highly conserved family of differentiation-regulated nuclear proteins that is highly expressed in nearly all human prostatic adenocarcinomas of Gleason Grade?5. This contrasts with the low percentage of prostate tumors that express molecular alterations in proto-oncogens or demonstrate tumor suppressor mutation or loss of heterozygosity. By analysis of specimens of human prostatic adenocarcinoma and paired adjacent normal prostate from three individual patients, the inventors have shown that normal prostate continues to express normal pp32, whereas three of three sets of RT-PCR-amplified transcripts from prostatic adenocarcinomas display multiple cancer-associated coding sequence changes. The cancer-associated sequence changes appear to be functionally significant. Normal pp32 exerts antineoplastic effects through suppression of transformation. In contrast, cancer-associated pp32 variants augment, rather than inhibit, transformation.Type: GrantFiled: June 12, 2000Date of Patent: August 16, 2005Assignee: The Johns Hopkins University School of MedicineInventors: Gary R. Pasternack, Gerald J. Kocheavar, Jonathan R. Brody, Shrihari S. Kadkol
-
Publication number: 20040247569Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.Type: ApplicationFiled: December 2, 2003Publication date: December 9, 2004Applicant: Intralytix, Inc.Inventors: J. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown